PharmaShots | Incisive News in 3 Shots

Subscribe Now

Merck kgaA

PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

May 24, 2024

Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

May 23, 2024

Merck KGaA and Inspirna Collaborate for the Development and Commercialization of Ompenaclid (RGX-202) for the Treatment of Colorectal Cancer

Merck KGaA and Inspirna Collaborate for the Development and Commercialization of Ompenaclid (RGX-202) for the Treatment of Colorec...

January 5, 2024

Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

December 6, 2023

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Cancer

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Canc...

October 31, 2023

Merck KGaA Reports P-III Trial (JAVELIN Bladder 100) Results of Bavencio (avelumab) in 1L Maintenance Treatment for Advanced Urothelial Carcinoma

Merck KGaA Reports P-III Trial (JAVELIN Bladder 100) Results of Bavencio (avelumab) in 1L Maintenance Treatment for Advanced Uroth...

February 14, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us